Neurocrine Biosciences Inc.

(NBIX) Trade

By |

Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Contact Information

Website: www.neurocrine.com
Email: ir@neurocrine.com
Main Phone: +1 858 617-7600
Address: 12780 El Camino Real
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92130

Issuer Information

Exchange: NGS
CEO: Kevin C. Gorman
Employees: 574
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)


Gathering Data... Please wait

Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Contact Information

Website: www.neurocrine.com
Email: ir@neurocrine.com
Main Phone: +1 858 617-7600
Address: 12780 El Camino Real
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92130

Issuer Information

Exchange: NGS
CEO: Kevin C. Gorman
Employees: 574
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 88.60 $ 0.62 (0.70%)
Last Price 88.60 Change $ 0.62 Change % 0.70 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open 88.02 High 89.69 Low 87.84 Prev Close 87.98
Last Trade Volume 563,363 52 Wk Hi 126.98 52 Wk Low 64.72
Market Cap 8 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 90,682,182.00 EPS (TTM) 0.06 PE Ratio 1,466.30 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 13 103
Number of Buys 5 35
Number of Sells 8 68
Net Activity 27377 -27712
Last 10 Buys Shares
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
W. Thomas Mitchell 1,000
Last 10 Sell Shares
Stephen A. Sherwin 1,000
Eric S. Benevich 1,000
Corinne H. Nevinny 1,000
Kevin C. Gorman 1,000
Darin Lippoldt 1,000
Kyle Gano 1,000
Haig P. Bozigian 1,000
Haig P. Bozigian 1,000
Gary A. Lyons 1,000
Dimitri E. Grigoriadis 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 139 139 139 139
Low Target Price Estimate 85 85 85 85
Mean Target Price Estimate 106 106 106.33 106
Standard Deviation 13.86 13.86 13.99 13.86
Date of Most Recent Estimate 05/29/18 05/29/18 05/14/18 05/29/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 10 10 11 11
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.09 1.09 1.08 1.08